Levobupivacaïne Fresenius Kabi (Levobupivacaine Hydrochloride)

Levobupivacaine works by reversibly blocking voltage‑gated sodium channels on nerve fibers. This inhibition prevents the initiation and propagation of action potentials, thereby stopping pain signals from reaching the brain and producing a localized anesthetic effect.

The specific dose of Levobupivacaïne Fresenius Kabi is determined by the prescribing clinician based on the type of procedure, patient characteristics, and desired depth of anesthesia. Healthcare professionals follow established guidelines and adjust the dose to achieve safe and effective analgesia.

Safety data for levobupivacaine in pregnancy and lactation are limited. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Levobupivacaine is the S‑enantiomer of bupivacaine and generally offers a similar duration of anesthesia with a lower risk of cardiotoxicity and central nervous system toxicity. Both agents provide effective regional blocks, but levobupivacaine is often preferred when a safer cardiac profile is desired.

The product should be stored below 25 °C, in its original packaging, protected from light and moisture. It must be kept out of reach of children and handled using aseptic technique to maintain sterility before epidural administration.

Levobupivacaïne is administered by a trained clinician via the epidural route. The solution is injected into the epidural space using a sterile technique, often after confirming correct needle placement by aspiration and, when appropriate, using imaging guidance.

Serious risks include cardiac arrest, severe hypotension, seizures, and allergic reactions such as anaphylaxis. These events are rare but require immediate medical intervention, continuous monitoring, and readiness to manage cardiovascular or respiratory complications.

Patients with known hypersensitivity to levobupivacaine or other amide‑type local anesthetics, those with significant cardiac conduction disorders, or individuals with uncontrolled severe hepatic impairment should avoid this medication. The decision should be individualized by the treating physician.